

formoterol degradation products level lower than 10% w/w with respect to the theoretical formoterol fumarate content of 6 µg/actuation and the residual level of formoterol fumarate is higher than 90 w/w with respect to its initial content.

- 5 18. A method according to claim 16 or 17 further characterised by the fact that the overall formoterol degradation products level is lower than 2% w/w with respect to the theoretical formoterol fumarate content of 6 µg/actuation and the residual level of the formoterol fumarate is higher than 95% w/w with respect to its initial content.

- 10 19. ~~A~~Use of a pharmaceutical aerosol solution composition as defined in any one of claims 1 to 14 for use in the prevention and/or treatment of an obstructive respiratory disorder selected from asthma and COPD.

- 15 20. Use of a pharmaceutical aerosol solution composition as defined in any one of claims 1 to 14 in the manufacture of a medicament for the prevention and/or treatment of an obstructive respiratory disorder selected from asthma and COPD.